The Clinical Times
The Front Page of Medicine

Latest medical news · page 205

The latest headlines across every section, pulled from official and open-access sources.

MedlinePlus (NLM) · Jun 9, 2026

Pedestrian Safety

Source: National Highway Traffic Safety Administration Related MedlinePlus Pages: Safety

ADA (Diabetes) · Jun 9, 2026

The American Diabetes Association Applauds Maryland for Removing Barriers to Obesity Treatment Coverage

The American Diabetes Association Applauds Maryland for Removing Barriers to Obesity Treatment Coverage mcarmody Tue, 06/09/2026 - 19:38 Advocacy News The American Diabetes Association Applauds Maryland for Removing Barriers to Obesity Treatment Coverage Annapolis, MD June 9, 2026 The American Diabetes Association ® (ADA) applauds the Maryland General Assembly for passing Senate Bill 496 allowing Maryland Medicaid to cover full obesity treatments, including weight-loss medications, if the state chooses to do so, and notifies patients. The strong bipartisan support from the Maryland General…

ACP · Jun 9, 2026

ACP strongly opposed to proposed changes to research funding

Statement attributable to: Jan K. Carney, MD, MPH, MACP President, American College of Physicians WASHINGTON, June 9, 2026—The American College of Physicians (ACP) is deeply concerned about the Office of Management and Budget’s proposed changes to the rules governing federal grants. The proposed rules would direct “senior appointees” at federal agencies to take charge of awarding and terminating new and existing research grants and other federal awards. As an organization with a mission to promote evidence-based medicine, we know the value of independent review by clinical and scientific…

MedCity News · Jun 9, 2026

GSK Gets a Pair of Near-Commercial Lung Cancer Drugs via $10.6B Nuvalent Acquisition

GSK’s Nuvalent acquisition brings two lead programs, each addressing different targets for non-small cell lung cancer. The Nuvalent lung cancer drugs are under FDA review and if they’re approved, GSK plans to launch both this year. The post GSK Gets a Pair of Near-Commercial Lung Cancer Drugs via $10.6B Nuvalent Acquisition appeared first on MedCity News .

FDA Recalls · Jun 9, 2026

Clover Hill Dairy Recalls Soft Ricotta/Requeson Cheese Due to Possible Health Risk

June 5, 2026 - Clover Hill Dairy of Mechanicsville, Maryland is voluntarily recalling all Soft Ricotta/Requeson Cheese because it has the potential to be contaminated with Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly p

FDA Drugs · Jun 9, 2026

Mitigating Risks of Compounded Drugs Through Surveillance

Mitigating Risks of Compounded Drugs Through Surveillance: The FDA reviews adverse event and product quality reports, and takes action to mitigate identified risks. We also raise awareness about risks related to human drug compounding.

FDA Drugs · Jun 9, 2026

Compounding Safety Information: Quinacrine Hydrochloride

Quinacrine appears on the FDA 503B list of bulk drug substances that may be used in ccompounded drugs. FDA’s review for the 503B Bulks List determined that there is a clinical need for drug products compounded from quinacrine in the treatment of some patients with cutaneous lupus erythematosus.

ACP · Jun 9, 2026

Internal Medicine Physician and Former ACP President named AMA President-Elect

PHILADELPHIA, June 9, 2026— Former American College of Physicians (ACP) President, Sandra A. Fryhofer, MD, MACP, was elected the American Medical Association (AMA) President-Elect at the AMA House of Delegates Annual Meeting in Chicago earlier today.  Dr. Fryhofer will be AMA President-Elect 2026 to 2027 and will assume the role of AMA President the following year. “Dr. Fryhofer has been a strong advocate for internal medicine, physicians, and our patients for years,” said Jan K. Carney, MD, MPH, president, ACP. “With her background in public health, her work in vaccine advocacy, and her…

PLOS Medicine · Jun 9, 2026

Molecular Tumor Boards clinical impact on patient care and structural features: A systematic review and meta-analysis

by Luigi Russo, Erika Giacobini, Nicolò Lentini, Tommaso Osti, Maud Kamal, Stefania Boccia, Roberta Pastorino Background Molecular Tumor Boards (MTBs) bring together multidisciplinary experts to translate genomic data into clinical decisions in oncology, however, their overall clinical impact remains unclear. The aim of this systematic review is to assess the clinical impact of MTB-recommended therapies on patients with cancer outcomes. Methods and findings In this systematic review and meta-analysis, we searched PubMed, Embase, Scopus, and CENTRAL up to July 2025. We included studies of any…

PLOS Medicine · Jun 9, 2026

Prediction of hospitalisation in young children with pneumonia in Malawi: A machine learning-based approach

by Patrick Staunton, Mohammad Adib Makrooni, Master Chisale, Billy Nyambolo, Joseph Wu, Damien McCarthy, Mark Ledwidge, Yasir Bin Nisar, Chris Watson, Balwani Mbakaya, Cathal Seoighe, Joe Gallagher Background Globally, pneumonia remains the single biggest cause of mortality in children under 5 years of age. This study sought to train and test a prediction model for hospitalisation within 7 days after initial presentation in 2- to 59-month-old Malawian children with WHO-defined pneumonia in primary care and compare its performance to existing risk prediction models. Methods and findings BIOTOPE…

MedCity News · Jun 9, 2026

Healthcare’s Assurance Infrastructure Is Broken. The Compliance Industry Built It That Way

SOC 2, HITRUST, and BAAs should be treated as starting points, not trust signals. They tell you what a vendor claims about its controls. They do not tell you whether those controls are actually working today or whether the evidence behind the attestation was real. The post Healthcare’s Assurance Infrastructure Is Broken. The Compliance Industry Built It That Way appeared first on MedCity News .

← NewerOlder →

Back to the live front page